AKT1 and hepatocellular carcinoma: Besides, lncTTN-AS1 expression is upregulated in HCC cells, and lncTTN-AS1 acts as a sponge for miR-16-5p to inhibit its expression, thereby upregulating cyclinE1, the target protein of miR-16-5p, and activating the PTEM/AKT signaling pathway, ultimately leading to resistance of HCC cells to sorafenib (93).